Noticias

Hims & Hers (NYSE:HIMS) is dominating headlines this week because the GLP-1 darling just delivered one of the ugliest quarters in the telehealth sector’s short history, and bargain hunters are circling the wreckage. But here’s what you should actually be watching. The Q1 2026 release on May 11, 2026 was a fracture. EPS came in ... Forget Hims. Its CEO Dumped 436,000 Shares Before a 1,266% Earnings Miss. Here Is the Profitable Healthcare Stock to Own Instead

Teladoc Health (NYSE:TDOC) reported first-quarter 2026 results that Chief Executive Officer Chuck Divita said came in above the midpoint of the company’s guidance for both revenue and Adjusted EBITDA, driven by solid performance in Integrated Care and continued progress scaling BetterHelp’s insuranc

Moby summary of Teladoc Health, Inc.'s Q1 2026 earnings call

Teladoc Health Inc (TDOC) reports robust revenue growth and strategic advancements in AI and insurance, despite challenges in cash flow and business model shifts.

Teladoc (TDOC) delivered earnings and revenue surprises of -13.82% and +0.25%, respectively, for the quarter ended March 2026. Do the numbers hold clues to what lies ahead for the stock?